三氟尿苷/替吡拉西在西伯利亚国家综合医院治疗难治性转移性癌症患者的疗效和耐受性

Q4 Medicine

Libri Oncologici Pub Date : 2021-12-22 DOI:10.20471/lo.2021.49.02-03.10

Lana Jajac-Bručić, F. Grubišić-Čabo, Josipa Jović-Zlatović, I. Krečak

{"title":"三氟尿苷/替吡拉西在西伯利亚国家综合医院治疗难治性转移性癌症患者的疗效和耐受性","authors":"Lana Jajac-Bručić, F. Grubišić-Čabo, Josipa Jović-Zlatović, I. Krečak","doi":"10.20471/lo.2021.49.02-03.10","DOIUrl":null,"url":null,"abstract":"In randomized clinical trials, trifluridine / tipiracil (TT) demonstrated beneficial effects on progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). The aim of this unicentric study was to evaluate the efficacy and safety of TT in patients with refractory mCRC in everyday clinical practice. Treatment outcomes of 20 patients were retrospectively analyzed. The median OS was 6.25 months (range 1-18) and the median PFS was 3 months (range 2–13). The most common (80%) side effect of TT was neutropenia and 35% of patients had neutropenia grades 3 of 4; however, only two patients (10%) had neutropenic fever and no deaths were attributable to neutropenia. In conclusion, treatment outcomes in this real-life study seem comparable to those from randomized clinical trials.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the general hospital of Šibenik-Knin country\",\"authors\":\"Lana Jajac-Bručić, F. Grubišić-Čabo, Josipa Jović-Zlatović, I. Krečak\",\"doi\":\"10.20471/lo.2021.49.02-03.10\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In randomized clinical trials, trifluridine / tipiracil (TT) demonstrated beneficial effects on progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). The aim of this unicentric study was to evaluate the efficacy and safety of TT in patients with refractory mCRC in everyday clinical practice. Treatment outcomes of 20 patients were retrospectively analyzed. The median OS was 6.25 months (range 1-18) and the median PFS was 3 months (range 2–13). The most common (80%) side effect of TT was neutropenia and 35% of patients had neutropenia grades 3 of 4; however, only two patients (10%) had neutropenic fever and no deaths were attributable to neutropenia. In conclusion, treatment outcomes in this real-life study seem comparable to those from randomized clinical trials.\",\"PeriodicalId\":53700,\"journal\":{\"name\":\"Libri Oncologici\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Libri Oncologici\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20471/lo.2021.49.02-03.10\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Libri Oncologici","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20471/lo.2021.49.02-03.10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

在随机临床试验中，三氟尿苷/替吡拉西（TT）对难治性转移性癌症（mCRC）患者的无进展生存期（PFS）和总生存期（OS）具有有益影响。这项单中心研究的目的是评估TT在日常临床实践中对难治性mCRC患者的疗效和安全性。对20例患者的治疗结果进行回顾性分析。OS中位数为6.25个月（1-18），PFS中位数为3个月（2-13）。TT最常见（80%）的副作用是中性粒细胞减少症，35%的患者有4级中的3级；然而，只有两名患者（10%）出现中性粒细胞减少热，没有死亡可归因于中性粒细胞降低。总之，这项真实研究的治疗结果似乎与随机临床试验的结果相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the general hospital of Šibenik-Knin country

In randomized clinical trials, trifluridine / tipiracil (TT) demonstrated beneficial effects on progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). The aim of this unicentric study was to evaluate the efficacy and safety of TT in patients with refractory mCRC in everyday clinical practice. Treatment outcomes of 20 patients were retrospectively analyzed. The median OS was 6.25 months (range 1-18) and the median PFS was 3 months (range 2–13). The most common (80%) side effect of TT was neutropenia and 35% of patients had neutropenia grades 3 of 4; however, only two patients (10%) had neutropenic fever and no deaths were attributable to neutropenia. In conclusion, treatment outcomes in this real-life study seem comparable to those from randomized clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Libri Oncologici Medicine-Oncology

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： - Genitourinary cancer: the potential role of imaging - Hemoglobin level and neoadjuvant chemoradiation in patients with locally advanced cervical carcinoma